Multiple sclerosis (MS) can present with varying clinical patterns, mainly characterized by an interplay between acute episodes of worsening (relapses or attacks) and a gradual neurologic deterioration (progression). Whether these distinct phenotypes represent one or several diseases has been a matter of debate. In the past two decades, worldwide natural history studies have provided arguments towards a unifying concept. In this perspective, comparison of the progressive forms of MS be it right from onset or after a relapsing-remitting phase was a major piece of evidence.
The progressive phase is considered, deservedly, as an unfavourable outcome and a major source of disability in MS. Therefore, primary progressive multiple sclerosis (PPMS) has long been considered as the worse phenotype, leading to a much more rapid accumulation of disability than relapsing-remitting multiple sclerosis (RRMS) or even secondary progressive multiple sclerosis (SPMS). This statement is true, when looking at the time window since the clinical onset of the disease. Nevertheless, it might as well be false, as it did not account for a major potential confounder, that is, age at MS onset.
In 2006, in the same issue of Brain, two cohorts in parallel, London, Ontario, and Lyon, France, proposed an original way of analysing their data, introducing a new endpoint, age at time of progression and disability. [1] [2] [3] Age might be considered as a survival data, that is, time from birth to the occurrence of the outcome. It provides the opportunity of decreasing, if not suppressing, the impact of age at MS onset that is 10 years younger in relapsing than in progressive onset patients.
The London Ontario group 1 compared three phenotypes with a progressive phase, preceded either by no relapse (PPMS), a single one (single attack progressive-multiple sclerosis, SAP-MS) or several ones (SPMS). Mean age at onset of progression was similar in all groups, 38.6, 40.9 and 39.2 years, respectively, for PPMS, SAP-MS and SPMS, whereas there was as expected a 10-year difference in age at MS onset. Furthermore, subsequent disability accumulation was comparable, irrespective of the number of relapses before onset of progression, in contrast with what was previously described as a worse prognosis in PPMS.
In two companion papers, Confavreux and Vukusic 2-3 compared, in the Lyon MS database, the demographic, clinical and prognostic characteristics of the four phenotypes described by Lublin and Reingold 4 in 1996. Here again, the median age at onset of progression was comparable, 40.1 years for PPMS and 39.1 years for SPMS, and ages at assignment of Disability Status Scale (DSS) 4, DSS6 and DSS7 in relapsing versus progressive onset MS patients were only marginally different, by 0-2 years, which is not clinically relevant.
Later on, these results have been confirmed by other teams, noticeably from Groningen and the Mayo Clinic groups, and a re-analysis of the London Ontario data. [5] [6] [7] These observations suggest that the clinical phenotype of MS, that is, the relapsing and the progressive phase of the disease, and the course of MS in terms of disability accumulation are, at least in part, an agedependent process.
It might be argued that this interpretation suffers many limitations. The major one is definitely methodological, as elegantly suggested by Tremlett et al. 8 in 2009. Comparing age at progression in PPMS versus SPMS could be biased by the use of observed data only, excluding by principle those patients with a relapsing onset who did not experience yet progression but should in the future, if followed for a sufficient time. That leads probably to an underestimation of the true age at onset of progression in patients with a relapsing onset.
Other sources of limitations are more clinical, depending on what we see and what we measure. What we see of a clinical history might be like looking through 
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S Vukusic a keyhole: you might not be able to see what happens on the right, the future or on the left, the past history. A patient classified initially as PPMS might experience further well-defined relapses later, or might in retrospect recall a past relapse, changing the classification into progressive-relapsing or SPMS. Our ability of detecting preceding clinical activity depends not only on questioning the patient but also on detecting pre-clinical activity on magnetic resonance imaging (MRI). In a series of 453 radiologically isolated syndromes, Kantarci et al. 9 found that 11.7% of the converters to MS directly entered a progressive disease, which is exactly what is expected from an MS population. Should those patients be classified as PPMS, or reclassified as SPMS, considering that activity is defined on clinical and/or radiological data in the 2013 revision of the Lublin classification? 10 What we measure might suffer from a differential measure bias. Determining onset of progression is probably much easier in a previously asymptomatic patient, like in PPMS, and much more difficult in the presence of persisting clinical activity or disability. Therefore, detecting onset of progression in SPMS patients might be delayed compared to PPMS. In this setting, disability measures, although criticized, could be more robust outcomes than progression. Another limitation comes from the use of DSS or Expanded Disability Status Scale (EDSS), which mainly relies on ambulation in these natural history studies, but underestimate the impact of cognitive disturbances, that could appear differently, maybe at a younger age, in SPMS than in PPMS patients, due to a greater lesion load. Finally, in the most recent series, it can be questioned whether age at onset of progression in SPMS patients might be delayed by a wide exposure to disease-modifying drugs, leading to an overestimate compared to PPMS.
To conclude, despite all sources of potential and contradictory biases that can be opposed, I would plead that age at onset of progression is essentially similar in PPMS and SPMS, of course at a population level that should not hide the wide range of ages experienced at the individual level. Small differences should not change the current vision of MS being a unique but complex disease, rather than heterogeneous. In the future, this position might impact the design of clinical trials of potentially neuroprotective drugs in the progressive phase of MS.
